SYNCHRONIZE Trial
The SYNCHRONIZE Phase 3 clinical trial program evaluates survodutide, an investigational glucagon/GLP-1 receptor dual agonist, in adults with overweight or obesity and related metabolic conditions.
-
Dr Jaime Almandoz
-
Professor Martin Haluzík
Exploring the metabolic and weight-management benefits of glucagon–GLP-1 dual receptor agonism.
-
Professor Lee M. Kaplan
Phase 3 survodutide outcomes in adults with overweight or obesity and MASLD.
-
Professor Matthias H. Tschöp
Exploring the rationale for glucagon receptor agonism and its potential metabolic benefits
-
Professor Carel le Roux
